MGX · Metagenomi Therapeutics Inc
United States · RS rating 6 · As of 2026-10-14
| Price | 0.86 USD |
|---|---|
| 1-day change | -6.1% |
| RS rating (overall / 1M / 3M / 12M) | 6 / 8 / 11 / 9 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 19 / 13 / 24 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -19.7% |
| Sales growth Q/Q | -54.8% |
| Distance from 52-week high | +74.3% |
| Market cap (USD) | $53.8M |